GlassScriptPhysician profile
C Adrien Bodet
NPI 1356362289
$1,541.80
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $372 · 2021: $241 · 2022: $620.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $455.86 | 2019-2022 | |
| Insmed, INC. | $455.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $182.27 | 2019-2022 | |
| Abbvie INC. | $171.89 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $75.72 | 2019-2022 | |
| Theratechnologies INC. | $45.30 | 2020-2022 | |
| Melinta Therapeutics, LLC | $40.30 | 2019-2022 | |
| Tetraphase Pharmaceuticals, INC. | $39.78 | 2019 | |
| Nabriva Therapeutics, Plc | $32.15 | 2020 | |
| Mayne Pharma Commercial LLC | $22.89 | 2022 | |
| Gilead Sciences, INC. | $20.58 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw C Bodet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.